英国生物技术为ALS和Parkinson的临床试验推出新药。 UK biotech raises $67M to advance new drug for ALS and Parkinson's into clinical trials.

英国生物技术NRG治疗机构筹集了5 000万英镑(6 700万美元)的B系列资金,以推进其主要药物NRG5051用于ALS/MND和帕金森病临床试验。 UK biotech NRG Therapeutics raised £50 million ($67 million) in Series B funding to advance its lead drug NRG5051 into clinical trials for ALS/MND and Parkinson's disease. 这笔资金由痴呆症发现基金牵头,将有助于产生概念临床证明和有意义的数据。 The funding, led by the Dementia Discovery Fund, will help generate clinical proof of concept and meaningful data. 药物针对的是线粒体功能失调,显示出神经保护效应,并减少了临床前模型中的神经发炎。 The drug targets mitochondrial dysfunction, showing neuroprotective effects and reduced neuroinflammation in pre-clinical models.